Unlock instant, AI-driven research and patent intelligence for your innovation.

Method for producing recombinant human serum albumin by using human hepatoma carcinoma cell HepG2/C3A as bioreactor

A protein and cell membrane technology used in the field of recombinant human serum albumin production

Active Publication Date: 2021-10-12
上海安民生物技术有限公司
View PDF11 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Second, the recombinant albumin expressed from human cells does not have glycosylation modification, and there is no immunogenic problem caused by the glycosylation modification of rHSA in the rice expression system

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for producing recombinant human serum albumin by using human hepatoma carcinoma cell HepG2/C3A as bioreactor
  • Method for producing recombinant human serum albumin by using human hepatoma carcinoma cell HepG2/C3A as bioreactor
  • Method for producing recombinant human serum albumin by using human hepatoma carcinoma cell HepG2/C3A as bioreactor

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0052] Example 1 Construction of vector PGK810 expressing AKT1 gene (myriAKT1) containing SRC protein membrane localization signal and activated MEK1S2E gene

[0053] myriAKT1 and MEK1SS2EE genes are linked by IRES (myriAKT1-IRES-MEK1SS2EE, see figure 1 ). The AKT1 gene (SEQ ID NO: 3) containing the coding sequence and amino acid sequence (SEQ ID NO: 1, 2) of the SRC protein myristylation peptide at the 5' end was fully synthesized, and the amino acid sequence obtained by expression is shown in SEQ ID NO: 4. Totally synthetic IRES fragment (SEQ ID NO: 5). The MEK1SS2EE gene (SEQ ID NO: 6) and the amino acid sequence of MEK1SS2EE (SEQ ID NO: 7) were synthesized. Using the vector part of PGK-H2BmCherry (Addgene Plasmid #21217) digested with restriction endonucleases BamHI and SalI as the backbone, myriAKT1, IRES and MEK1SS2EE were spliced ​​and connected to the BamHI of the PGK-H2BmCherry vector by multi-fragment recombination splicing and SalI site, the vector PGK810 was obt...

Embodiment 2

[0054] Embodiment 2 prepares PGK810 virus

[0055] Taking 1 well in a six-well plate as an example, each sample needs 1.3×10 6 293T cells.

[0056] 1. On the first day, plant 1.3×10 cells in 6-Well cell culture wells 6 293T cells, the cell culture medium is 2mlDMEM(GIBCO)+10%FBS(GIBCO). Set at 37°C, 5% CO 2 Incubator for 16 hours.

[0057] 2. On the second day, take a 1.5ml sterilized EP tube, add 1.6μg PGK810 plasmid, 1.2μg packaging auxiliary plasmid PAX2 and 0.8μg packaging auxiliary plasmid VSV-G, add 200μl opti-MEM, let stand for 5 minutes, then add 10.8 μl liposome transfection reagent Fugene HD (Roche), let stand for 15 minutes.

[0058] 3. Evenly add opti-MEM containing DNA and Fugene HD liposomes to 293T cells in 6-Well, mix slightly, and return the cells to 37°C, 5% CO 2 The cell culture incubator was continued for 12 hours.

[0059] 4. 12 hours after transfection, replace the medium in the 6-Well with 2ml fresh DMEM+10%FBS fully preheated, and place at 37°C, ...

Embodiment 3

[0061] Example 3 PGK810 virus infection of C3A cells and serum-free screening

[0062] 1, 1.3×10 6 C3A cells (ATCC Number: CRL-10741) were planted in 10cm cell culture dish with 10ml DMEM / F12 medium containing 10%FBS, 37℃, 5%CO 2 The incubator cultivated for 12hr.

[0063] 2. Add 12μl 8mg / ml polybrene to the petri dish and mix well, add 2ml of PGK810 virus, continue culturing for 12hrs and replace with fresh medium.

[0064] 3. After continuing to cultivate for 36 hours, replace the original medium with 10ml of fresh medium, and continue to cultivate for 24 hours.

[0065] 4. Digest the cells with trypsin, inoculate them in fresh medium and a new culture dish at a ratio of 1:5, after 24 hours, replace with serum-free DMEM / F12 medium, and continue to culture for 72 hours.

[0066] 5. Collect all suspended cells, digest unsuspended adherent cells with trypsin, combine all cells, inoculate in fresh serum-free DMEM / F12 medium at a ratio of 1:5, and continue to culture for 24 ho...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a method for producing recombinant human serum albumin by using human hepatoma carcinoma cell HepG2 / C3A as bioreactor. Activated AKT1 and activated MEK1 are simultaneously and stably expressed in a human hepatoma cell line HepG2 / C3A, and a human hepatoma cell population C3A810 capable of growing in a complete chemical component limited culture medium without serum addition and growth factor addition is obtained for the first time. The cell population is used as a reactor for successful recombinant expression of human serum albumin (HSA), which indicates that the cell population can be used as a reactor of plasma protein drugs including human serum albumin, human serum albumin fused cell long-acting cytokines and other recombinant protein drugs for human.

Description

technical field [0001] The invention belongs to the field of biotechnology, and in particular relates to a method for producing recombinant human serum albumin by using human liver cancer cell HepG2 / C3A as a bioreactor. Background technique [0002] Therapeutic recombinant protein is a class of drugs produced by biotechnology and used to compensate for the lack or defect of a certain protein in the body that causes diseases. Today, more than thousands of recombinant protein drugs have been approved for marketing around the world, among which antibody drugs have become the most important biological drugs. The commercial importance and demand for therapeutic recombinant protein products is still growing rapidly year by year [1-3]. [0003] There are a variety of reactors (cell expression systems) for the production of recombinant protein drugs, including bacterial cells, yeast cells, plant cells, insect cells, and mammalian cells (including human cells). The most suitable ex...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12N15/867C12N15/54C12N15/12C12N9/12C12N5/10C12N7/01C07K14/765C12R1/91
CPCC12N15/86C12N9/1205C12N7/00C07K14/765C12N2740/15021C12N2740/15043C12N2800/107
Inventor 朱颂成赵晓梅倪华
Owner 上海安民生物技术有限公司